Clinical trial
An Open-label, Cross-over, Dose-ranging Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of the Subcutaneous Administration of a Human Plasma-derived C1-esterase Inhibitor in Subjects With Hereditary Angioedema
NCT01576523 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Cross-over, Dose-ranging Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of the Subcutaneous Administration of a Human Plasma-derived C1-esterase Inhibitor in Subjects With Hereditary Angioedema
- Lead sponsor
- CSL Behring
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- April 30, 2012
- Completion date
- December 31, 2012
- Enrollment
- 18 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.